and can disproportionate to nitrate and NO (eqn 2).
3HONO H
It can, therefore, be assumed that NO − # could act as an indirect vasodilator.
In an article recently published in Clinical Science, Demoncheaux et al. [1] [2] ) is a directly acting vasodilator, unlike other circulating carriers of NO, such as S-nitrosothiols (RSNOs), notably Snitrosoalbumin and S-nitrosohaemoglobin. In our opinion, this conclusion is incorrect.
We think that the findings by Demoncheaux et al. [1] can be explained by the assumption that NO − # , i.e. HONO, acts indirectly as a vasodilator, i.e. by reacting with the sulphydryl group of thiols (RSHs) to form the very potent vasodilator RSNOs (eqn 3), the vasodilator activity of which may be severalfold higher (e.g. 80-fold higher for S-nitrosocysteine [3] ) than that of authentic NO.
HONOjRSH H # OjRSNO
It must be noted that RSNOs can exert NO-related biological activities without releasing NO [4] , a fact that may explain their higher potency over NO. Remarkably, in the human forearm circulation, intra-arterial infusion of S-nitrosoglutathione at 0.2 nmol\min completely inhibited platelet aggregation [5] . Demoncheaux et al. [1] did [
Consequently, the equilibrium concentration of RSNOs,
[RSNO] eq , must also depend on pH in a similar fashion. Indeed, Figure 1 shows that the experimentally observed pH profile of three RSNOs parallels that of calculated [HONO] eq . It can be expected that at pH 7.4, the ratio of
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We thank Tsikas and Fro$ lich for their interest in our article [1] , and are pleased to respond to their comments and further address the issue of monitoring reactive nitrogen species in biological milieu. We have demonstrated that although free nitric oxide (NO) is at equilibrium with nitrite (NO − # )\nitrous acid (HONO), the amount of NO in the presence of NO − # is insufficient to cause vasodilation. Our methodology allowed us to precisely monitor NO interfacial kinetics in aerated Krebs bicarbonate at 37 mC, providing us with the confidence to apply our estimates to organ baths containing pre-contracted pulmonary arteries from pigs. Finally, the extensive surface area for gas exchange that a lung offers [2] allowed us to further ascertain the presence of NO in circulating pools of NO − # . Tsikas and Fro$ lich argue that the effect we reported [1] might not implicate a direct action of NO − # . They further suggest, on the basis of data published by their laboratories, that the reaction of HONO with thiols (RSHs) to give RSNOs may be responsible for the activity we reported.
RSHs are known to decrease NO activity in vitro [3] , although on the contrary we agree with Tsikas and Fro$ lich that the vasodilatory activity of RSNOs (or thionitrites) is well documented (reviewed in [4] ). We also agree that HONO reacts readily with RSHs and that it was an oversight not to have raised this possibility. In self-defence, we would point out that our arterial tissue rings were not blood perfused and therefore it is doubtful that there would have been sufficient reactive RSHs present to account for the activity. We did not measure the concentrations of any of the implicated ' NO carriers ', such as cysteine, glutathione or albumin. We agree that the issue here is less one of stoichiometry than bioactivity. [5] [6] [7] [8] , reflecting complex equilibria between nitrogen oxides and oxyacids both in the gas and liquid phase [7] . We believe that an understanding of these equilibria in functional experiments of NO bioactivity, such as in organ bath studies, is extremely important.
The exact properties of an RSH, including highmolecular mass, i.e. protein RSHs, that would predispose it to RSNO formation and\or the ability to deliver an ' endothelium-derived relaxing factor (EDRF) response ' are not known [9] . Many studies have been performed to characterize the EDRF response [10] [11] [12] [13] [14] [15] . RSNOs have differing pharmacokinetics and pharmacodynamic properties to NO vis-a' -vis vasodilatory properties [16, 17] , but the molecular mechanism by which they act is unknown (excepting via dissociation to free NO and via the standard guanylate cyclase\kinase mechanism). Does RSNO act on the haem moiety of guanylate cyclase ? Or does it act directly via trans-nitrosation on cysteine RSHs in ion channels or other proteins [18, 19] ? It is possible that the action of RSNOs is not direct, but due to their equilibrium with other nitrogen oxides, e.g. NO − # . In summary, we agree that the study of the fate of NO in biological milieu is of considerable importance. We would also like to further emphasize the complexity of the chemistry of reactive nitrogen species in biological systems [20] . It is our opinion that the jury is still out on the relative importance of all the oxides of nitrogen and their physiological adducts including NO − # , RSNOs, nitrated proteins and nitrosylated metalloproteins. Monitoring reactive nitrogen species in biological milieu is a challenging endeavour and selective methods to measure endogenous NO production in vivo will certainly help unravel the complex interactions between nitrogen oxides and their derivatives [21] . The role of the NO − # anion in vivo is still speculative. Nevertheless, we feel that evidence has now accumulated indicating that it may play a crucial, but hitherto underestimated, role as an EDRF carrier in the body.
